Testing a new oral drug for treating high-grade astrocytomas
Phase I study to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of WSD0922-FU
This study is testing a new oral medication called WSD0922-FU to see how safe and effective it is for people with high-grade astrocytomas, a tough type of brain cancer, and it aims to find the best dose while keeping an eye on any side effects and how well the drug helps shrink tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10479857 on NIH RePORTER |
What this research studies
This research investigates the safety and effectiveness of a new oral drug called WSD0922-FU for patients with high-grade astrocytomas, a rare and aggressive type of brain cancer. The study aims to determine the maximum tolerated dose of the drug and how well it can inhibit tumor growth by targeting specific genetic alterations in the cancer cells. Patients will be monitored for side effects and how the drug affects their tumors over time. The trial is designed to gather important data that could lead to improved treatment options for this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade astrocytomas who have specific genetic alterations such as EGFR amplification or the EGFRvIII mutation.
Not a fit: Patients with low-grade astrocytomas or those without the targeted genetic alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with high-grade astrocytomas that specifically targets their tumor's genetic characteristics.
How similar studies have performed: Previous research has shown promise in targeting EGFR alterations in other cancers, suggesting potential for success with this novel approach in high-grade astrocytomas.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kizilbash, Sani Haider — Mayo Clinic Rochester
- Study coordinator: Kizilbash, Sani Haider
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.